Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States.

Significant differences in health care resource utilization and costs were found across first-line metastatic melanoma regimens. Utilization rates were highest in patients using ipilimumab-containing therapies. High drug costs constituted a major fraction of total PPPM health care costs.